Meningococcal
Meningococcal (Men-C, ACYW, Men-B)
MENVEO · NIMENRIX · MENQUADFI · NEISVAC-C · BEXSERO · TRUMENBA
Routine toddler and adolescent doses; extra doses for higher-risk conditions. Every product below is a Health Canada authorized vaccine; every schedule comes from the Canadian Immunization Guide.
Products authorized in Canada
Brand names and DINs (Drug Identification Numbers) as Health Canada's Drug Product Database lists them. The product monograph is the manufacturer's full prescribing information approved by Health Canada.
| Product | DIN | What it is | Presentation and age | Official information |
|---|---|---|---|---|
| MENVEO | 02347393 | Meningococcal A, C, W-135, Y oligosaccharide conjugate | 0.5 mL · powder + solution (two vials) · intramuscular · 2 months and older | Product guideHealth Canada recordProduct monograph (PDF) |
| MENVEO | 02563029 | Meningococcal A, C, W-135, Y oligosaccharide conjugate | 0.5 mL · solution (liquid) · intramuscular · 2 months and older | Product guideHealth Canada recordProduct monograph (PDF) |
| NIMENRIX | 02402904 | Meningococcal A, C, W-135, Y polysaccharide conjugate | 0.5 mL · powder for solution · intramuscular · 6 weeks and older | Product guideHealth Canada recordProduct monograph (PDF) |
| MENQUADFI | 02507161 | Meningococcal A, C, W, Y polysaccharide conjugate | 0.5 mL · solution · intramuscular · 12 months and older | Product guideHealth Canada recordProduct monograph (PDF) |
| NEISVAC-C | 02245057 | Meningococcal group C polysaccharide conjugate | 0.5 mL · suspension · intramuscular · 2 months and older | Product guideHealth Canada recordProduct monograph (PDF) |
| BEXSERO | 02417030 | Meningococcal group B (4CMenB) | 0.5 mL · suspension · intramuscular · 2 months and older | Product guideHealth Canada recordProduct monograph (PDF) |
| TRUMENBA | 02468751 | Meningococcal group B (MenB-fHBP) | 60 mcg / 0.5 mL · suspension · intramuscular · 10 years and older | Product guideHealth Canada recordProduct monograph (PDF) |
Pregnancy and breastfeeding
Pregnancy
Recommended when there is a high-risk condition, travel, an exposure or an outbreak.
Breastfeeding
Recommended when there is a high-risk condition, travel, an exposure or an outbreak.
Source: Immunization in pregnancy and breastfeeding: Canadian Immunization Guide — Chapter updated August 2026. Live vaccines are generally contraindicated in pregnancy; routinely recommended vaccines can be given while breastfeeding unless the chapter says otherwise.
How many doses
The schedules the Canadian Immunization Guide describes for this vaccine. Which one applies depends on age, health and product — use the dose planner to see the dates for your situation.
| Schedule | Doses | Who it is for | Products |
|---|---|---|---|
| Meningococcal ACYW — toddler dose at 12 to 23 months One dose of quadrivalent (Men-C-ACYW) conjugate vaccine at 12 to 23 months. | 1 dose | NACI (May 2026): all children 12 to 23 months of age should receive one dose of quadrivalent meningococcal conjugate (Men-C-ACYW) vaccine, replacing the Men-C-C toddler dose. A child who already had Men-C-C at 12 to 23 months is not revaccinated. MENQUADFI is authorized from 12 months, NIMENRIX from 6 weeks, MENVEO from 2 months. | MENVEO, NIMENRIX, MENQUADFI |
| Meningococcal ACYW — routine adolescent or adult, one dose One dose of Men-C-ACYW conjugate vaccine, routinely given at about 12 years of age. | 1 dose | Routine single adolescent dose regardless of infant or toddler history; also for adults with travel, occupational or outbreak indications. | MENVEO, NIMENRIX, MENQUADFI |
| Meningococcal ACYW — high-risk conditions, two doses Two doses 8 weeks apart for asplenia, complement deficiency, HIV and other high-risk conditions. | 2 doses | For people 12 months and older with no spleen or a spleen that does not work, complement or properdin deficiency (including eculizumab or ravulizumab treatment), HIV, or other high-risk conditions. Two doses at least 8 weeks apart (4 weeks if accelerated). A booster every 5 years while risk continues (every 3 years if first immunized under 7 years of age). | MENVEO, NIMENRIX, MENQUADFI |
| Meningococcal C (NEISVAC-C) — toddler dose at 12 to 23 months (older provincial programs) One dose of Men-C-C conjugate vaccine at 12 to 23 months, where a province still uses it. | 1 dose | The CIG chapter recommends one dose of Men-C-C at 12 to 23 months regardless of infant doses. NACI (May 2026) now recommends a quadrivalent (Men-C-ACYW) dose at this age instead; a child who already had Men-C-C at 12 to 23 months is not revaccinated. | NEISVAC-C |
| Meningococcal B (BEXSERO) — infants starting at 2 to 5 months Two doses 8 weeks apart plus a booster at 12 to 23 months of age. | 3 doses | For infants starting at 2 to 5 months of age when recommended (high-risk conditions, outbreak control or provincial programs): two (or three) primary doses at least 8 weeks apart, then a booster in the second year of life (12 to 23 months of age). | BEXSERO |
| Meningococcal B (BEXSERO) — infants starting at 6 to 11 months Two doses at least 8 weeks apart plus a booster at 12 to 23 months of age. | 3 doses | For infants starting at 6 to 11 months of age: two doses at least 8 weeks apart, then a booster in the second year of life (12 to 23 months of age). | BEXSERO |
| Meningococcal B (BEXSERO) — 12 months to 10 years, two doses Two doses at least 8 weeks apart. | 2 doses | For children 12 months to 10 years of age at increased risk (asplenia, complement deficiency, outbreak) or by individual decision: two doses at least 8 weeks apart. | BEXSERO |
| Meningococcal B (BEXSERO) — 11 years and older, two doses Two doses at least 4 weeks apart. | 2 doses | For people 11 years of age and older at increased risk (asplenia, complement deficiency, laboratory exposure, outbreak) or by individual decision: two doses at least 4 weeks apart. | BEXSERO |
| Meningococcal B (TRUMENBA) — 10 years and older, two doses Two doses 6 months apart for people 10 years and older who are not at high risk. | 2 doses | TRUMENBA is authorized for 10 years of age and older. Routine two-dose schedule at 0 and 6 months. High-risk people need the three-dose schedule instead. | TRUMENBA |
| Meningococcal B (TRUMENBA) — high-risk conditions, three doses Three doses at 0, 1 to 2 and 6 months for high-risk people 10 years and older. | 3 doses | For asplenia, complement deficiency, HIV and other high-risk conditions from 10 years of age. Dose 2 at least 4 weeks after dose 1; dose 3 at least 4 months after dose 2 and at least 6 months after dose 1. | TRUMENBA |
Sources
- NACI rapid response: quadrivalent conjugate meningococcal vaccines in children under 2 years of age — Published May 2026
- Meningococcal vaccines: Canadian Immunization Guide — Chapter revised May 2015 · partial update March 2025
- Health Canada Drug Product Database — product records and monographs
Clinical rules reviewed on 2026-09-27. General information from public Canadian guidance; a personal assessment is needed for treatment decisions. Care365 does not decide whether a vaccine is publicly funded in Ontario.